€21.88 Pfizer (PFE.DE XETRA) 29 Jan 2026 ahead of earnings: guidance will set next move
Pfizer Inc. listed as PFE.DE on XETRA trades at €21.88 intraday on 29 Jan 2026, down -1.97% after an early session pullback as the market focuses on its earnings due 03 Feb 2026. PFE.DE stock faces a short-term test of guidance and sales for its vaccine and specialty portfolios. Volume sits around 39,147.00 shares versus an average of 58,108.00, showing below-average trading ahead of the report. We preview earnings drivers, valuation, and likely market reactions for Germany XETRA traders and EU investors
Market snapshot: PFE.DE stock intraday
Pfizer (PFE.DE) on XETRA is trading at €21.88, with a day low of €21.74 and a day high of €22.04. The stock is down -1.97% on the session and volume is 39,147.00, below the 50-day average of 58,108.00. The intraday move reflects profit-taking ahead of the 03 Feb 2026 earnings release and sector weakness in Healthcare
Earnings setup: PFE.DE earnings and the Feb 3 report
Pfizer reports results on 03 Feb 2026, and guidance will dominate the call. Investors will watch sales momentum for Comirnaty, Prevnar family, and Paxlovid plus margin progress. Recent headlines and price action are covered by major outlets, including Reuters and MarketWatch for background on revenue mix and market reaction source source
Fundamentals and valuation: PFE.DE analysis
Pfizer shows EPS 1.45 and PE 15.09 on the XETRA quote, with market cap near €124,374,852,700.00. Key ratios include price/Book 1.60, price/Sales 2.37, and free cash flow yield 0.07, supporting a value-oriented case. Revenue and EPS growth remain modest, with FY 2024 net income growth at 2.76%, and dividend yield showing steady cash return to shareholders
Technical and trading signals for PFE.DE stock
Technicals show a neutral RSI at 50.93 and MACD near zero, indicating limited trend momentum. Price sits close to the 50-day average €21.79 and 200-day average €21.27, so intraday moves will likely follow earnings news. Traders should watch intraday support at €21.74 and resistance at €22.39 (Bollinger upper band)
Meyka grade and forecast: PFE.DE stock outlook
Meyka AI rates PFE.DE with a score of 68.59 out of 100 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month target of €19.77, implying -9.67% from today’s €21.88; forecasts are model-based projections and not guarantees. Company rating detail (28 Jan 2026) shows an A- with a Buy view from external analysts, while our model recommends caution into earnings. These grades are not guaranteed and we are not financial advisors
Risks and catalysts for PFE.DE stock
Catalysts include clearer 2026 guidance, updates on vaccine contracts, and pipeline data readouts. Risks cover pricing pressure in Europe, biosimilar competition, and margin normalization that could widen downside. Near-term volatility is likely around the Feb 3 earnings release and management commentary
Final Thoughts
PFE.DE stock trades at €21.88 intraday on 29 Jan 2026 as investors position ahead of the 03 Feb 2026 earnings report. Key near-term drivers are management guidance, Comirnaty and Prevnar revenues, and Paxlovid demand. Our model price targets show a constructive scenario at €24.50, implying +11.97% upside, and a downside case at €18.00, implying -17.74% risk from today’s price. Meyka AI’s forecast model projects €19.77 over 12 months, implying -9.67% from current levels; forecasts are model-based projections and not guarantees. For traders on XETRA, keep position sizes tight and watch guidance for margin signals that will set the next directional move
FAQs
When does Pfizer (PFE.DE) release earnings and what matters most
Pfizer (PFE.DE) reports on 03 Feb 2026. Investors should focus on full-year guidance, Comirnaty and Prevnar sales, Paxlovid volume, and margin commentary, which will drive PFE.DE stock moves
What valuation metrics matter for PFE.DE stock
Key metrics for PFE.DE stock include PE 15.09, price/Book 1.60, free cash flow yield near 7.0%, and dividend sustainability. Watch EPS and FCF trends post-earnings
How does Meyka AI view PFE.DE stock right now
Meyka AI gives PFE.DE a 68.59/100 score (Grade B, HOLD). The assessment weighs sector, growth, metrics, and analyst views. It is informational and not investment advice
What are realistic near-term price targets for PFE.DE stock
Near-term scenarios show a bullish target of €24.50 (+11.97%) and a bearish level of €18.00 (-17.74%). Use earnings and guidance to update targets for PFE.DE stock
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
